Episode 5: CAR-T: How far have we come and where are we going?

February 27, 2020 PAREXEL

In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s experts Mo Heidaran, Alexander Gee and host Alberto Grignolo, all part of our newly-integrated Regulatory & Access consulting unit, also weigh in on the current regulatory and reimbursement landscape for CAR-T and what we might look forward to in the future for this and other cell and gene therapies.

Previous Article
Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients
Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients

Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how bi...

Next Article
Episode 4: Accelerated Regulatory Pathways and Patient Access
Episode 4: Accelerated Regulatory Pathways and Patient Access

In this episode, Parexel’s Mwango Kashoki, a former FDA regulator, and Richard Macaulay, who specializes in...